Cutaneous melanoma is the leading cause of skin cancer-related deaths and is notorious for its resistance to therapy. Nevertheless, recent targeted therapy trials have been promising 1, 2 . Notably, the Ras/Raf/ MEK/ERK pathway has been identified as a major, druggable regulator of melanoma 3 . Activating NRAS mutations are commonly observed in human melanoma, usually affecting codon 61 (refs. 4,5). BRAF is also frequently mutated 6 , most commonly resulting in a glutamic acid for valine substitution at position 600 (V600E) (ref. 6). BRAF (V600E), which results in constitutively overactive MAPK/ ERK signaling and melanocyte hyperproliferation 7 , has been successfully exploited for targeted therapy. PLX4032 (vemurafenib), a selective RAF inhibitor, showed an unprecedented antitumor response rate in patients with BRAF (V600E) (ref. 8) and conferred an overall survival benefit in a pivotal phase 3 study 9 . Unfortunately, most patients rapidly acquire resistance to vemurafenib 10 , highlighting the urgent need for new treatment strategies of BRAF (V600E)-induced melanoma.
Cutaneous melanoma is the leading cause of skin cancer-related deaths and is notorious for its resistance to therapy. Nevertheless, recent targeted therapy trials have been promising 1, 2 . Notably, the Ras/Raf/ MEK/ERK pathway has been identified as a major, druggable regulator of melanoma 3 . Activating NRAS mutations are commonly observed in human melanoma, usually affecting codon 61 (refs. 4,5) . BRAF is also frequently mutated 6 , most commonly resulting in a glutamic acid for valine substitution at position 600 (V600E) (ref. 6) .
BRAF (V600E), which results in constitutively overactive MAPK/ ERK signaling and melanocyte hyperproliferation 7 , has been successfully exploited for targeted therapy. PLX4032 (vemurafenib), a selective RAF inhibitor, showed an unprecedented antitumor response rate in patients with BRAF (V600E) (ref. 8) and conferred an overall survival benefit in a pivotal phase 3 study 9 . Unfortunately, most patients rapidly acquire resistance to vemurafenib 10 , highlighting the urgent need for new treatment strategies of BRAF (V600E)-induced melanoma.
Restoration of the wild-type p53 tumor suppressor function has emerged as an attractive anticancer strategy [11] [12] [13] . However, usefulness of this approach in melanoma is unclear; although inactivating mutations or allelic loss of TP53 are common in human cancers 14 , the TP53 locus is intact in >95% of melanomas 15 . Nevertheless, increasing evidence supports a role for p53 in melanomagenesis, as loss of p53 cooperates with activated HRAS V12G and BRAF V600E in mice 16, 17 and with oncogenic NRAS in zebrafish 18 , culminating in melanoma formation.
Cancers that retain wild-type p53 often find alternative ways to subvert p53 function, by deregulating upstream modulators and/or by inactivating downstream effectors 19 . For example, MDM2, which encodes an E3 ubiquitin ligase that controls p53 expression and function 20 , is amplified in 3-5% of human melanomas 21 .
Here we show that the p53 pathway is inactivated in the majority of cutaneous melanomas as a result of upregulated expression of MDM4, a key negative regulator of p53 (refs. 22,23) . We show that targeting the MDM4-p53 interaction inhibits the growth of melanoma cells and markedly sensitizes them to conventional chemotherapeutics. Notably, MDM4 inhibition affects the growth of melanoma cells that have acquired resistance to BRAF inhibitors and synergizes with BRAF 1 2 4 0 VOLUME 18 | NUMBER 8 | AUGUST 2012 nature medicine inhibitors to kill BRAF-mutant cells. These data identify the MDM4-p53 interaction as a new therapeutic target for melanoma treatment.
RESULTS

MDM4 is overexpressed in ~65% of human melanomas
To investigate whether MDM4 overexpression contributes to p53 inactivation in human melanomas, we assessed MDM4 protein expression in normal skin and in melanomas by immunofluorescence. Although detectable in the cytoplasm of epidermal keratinocytes, MDM4 expression was very low to undetectable in normal melanocytes (Fig. 1a) . Assessment of a panel of 54 primary cutaneous and metastatic melanomas showed variable MDM4 expression (from very low or undetectable to high), with MDM4 localizing to the nucleus in most cells (Fig. 1b) . We observed that MDM4 expression was significantly increased in 68.5% of melanomas compared with normal melanocytes (Fig. 1c) , including 56.7% of early stage (stage I or II) tumors and 83.3% of metastatic (stage III or IV) tumors (Fig. 1c) . We found no correlation between age (calculated as age at resection of tumor) or pathologic subtype and MDM4 expression (Supplementary Table 1 ). There was, however, a statistically significant correlation between high MDM4 expression and late-stage (stage III or IV) metastatic disease (Supplementary Table 1) . We confirmed MDM4 overexpression in an additional cohort of 40 freshly isolated human melanomas by immunoblotting (Fig. 1d) . Notably, in only 3 out of 40 of these samples were MDM4 mRNA levels comparable to or higher than those in the breast cancer cell line MCF-7, which is known to express high MDM4 mRNA levels ( Supplementary Fig. 1 ) 24 . In contrast, MDM4 protein expression was comparable to or higher than that observed in MCF-7 cells in 65% of cases ( Fig. 1d and Supplementary Table 2) . Consistent with the immunofluorescence data, MDM4 protein expression was either undetectable or very low in normal melanocytes and in benign nevi ( Fig. 1d and Supplementary Fig. 2a ). Six out of ten primary cutaneous tumors had high MDM4 levels (Fig. 1d) , supporting the possibility that MDM4 upregulation occurs early in melanomagenesis. In contrast, MDM2 protein expression levels ranged from undetectable to low in most cases (Fig. 1d) . We only found MDM2 expression levels comparable to those in U2OS cells, an osteosarcoma cell line highly expressing MDM2, in one out of ten regional dermal metastases, one out of ten nodal metastases and four out of ten distant metastases ( Fig. 1d and Supplementary Table 1) . Overexpression of MDM2 and MDM4 co-occurred in only 2 out of 30 metastatic melanomas (stage IV) (Fig. 1d) .
Compared with primary melanocytes, we found that MDM4 was also elevated in 14 out of 16 patient-derived short-term cultures established from metastatic tumors, as well as in four out of four cell lines (A375, WM9, Mel-501, Lu1205) harboring wild-type p53 ( Supplementary Fig. 2b ,c and Supplementary Table 3) . Consistent with the notion of a post-transcriptional mechanism being primarily responsible for MDM4 upregulation, MDM4 mRNA levels were higher than those in MCF-7 in only one of these cell lines (MM120; Supplementary Fig. 1b) . As in freshly isolated human melanoma samples, MDM2 protein expression levels ranged from undetectable to low in the majority of short-term cultures ( Supplementary  Fig. 2b,c) . We found that MDM2 levels were comparable to those in U2OS cells in four cell lines (MM011, MM034, MM061, MM117) and higher in only two cell lines (MM001, MM120; Supplementary  Table 3) . Notably, MDM2 was highly expressed in all (four out of four) well-established (Supplementary Fig. 2c ) melanoma cell lines, suggesting that extended in vitro passage might induce MDM2 expression.
We determined TP53, BRAF and NRAS mutational status in the primary tumors and cell lines described above ( Supplementary  Tables 2 and 3) . Consistent with previous reports 15, 25 26 ; however, melanomas develop only after a long latency and with low penetrance. To assess the role of p53 in these mice, we inactivated Trp53 in previously characterized null (-) and conditional (lox) knockout alleles 27, 28 . Melanocyte-specific deletion of one or two alleles of Trp53 cooperated with NRAS Q61K to induce spontaneous and aggressive melanoma formation (ref. 29 and Supplementary Fig. 3 ). 30 (Fig. 2a) . We crossed these double-transgenic mice onto a Trp53-heterozygous background to facilitate spontaneous tumor development. (Fig. 2b) . Melanomas were nodular, pigmented and (Fig. 2f ) . On average, there were more lesions per mouse in Mdm4-overexpressing mice than in controls (Fig. 2g) . Together, these data indicate that Mdm4 overexpression cooperates with the NRAS oncoprotein to promote aggressive melanoma formation in vivo.
MDM4 promotes cell proliferation and survival of human melanoma
To test whether human metastatic melanoma cells depend on high MDM4 expression for their survival and proliferation we knocked down MDM4 in short-term cultured (MM011, MM031, MM117) and commonly used metastatic melanoma cell lines (A375, Lu1205). Our choice of cell lines was motivated by the presence of high protein expression levels of MDM4, a genetically intact TP53 pathway and different ratios of MDM4/MDM2 protein expression levels. We targeted different regions of MDM4 mRNA using two lentiviral constructs (data shown below and in Supplementary Fig. 4 ). MM031 expressed high MDM4 and low MDM2 protein expression levels, which best represents the vast majority of melanoma lesions; MM011 and MM117 highly express both MDM4 and MDM2, which is characteristic of only a few human distant-metastatic melanomas. Western blotting confirmed efficient MDM4 knockdown in all cell lines ( Fig. 3a and Supplementary Fig. 5a ). Cell viability and colony formation assays showed that MDM4 knockdown caused robust growth inhibition in all melanoma lines analyzed (Fig. 3b,c and Supplementary Fig. 5b,c) .
Cell cycle analysis showed a reproducible and significant decrease in BrdU incorporation upon MDM4 knockdown ( Fig. 3d and  Supplementary Fig. 5d ). In addition to the reduced proliferation, increased cell death was evidenced by the increased sub-G1 fraction in the FACS profiles (data not shown). We found that cell death resulted, at least in part, from a reproducible and significant induction of caspase3/7 activity ( Fig. 3e and Supplementary Fig. 5) .
Some of the parental melanoma cell lines (MM031, Lu1205, A375) efficiently formed tumors when injected into nude mice (8-weekold Rj:NMRI-nu (nu/nu) female mice). We show that MDM4 knockdown strongly reduces the transforming potential of these cells in vivo (Supplementary Figs. 5f and 6 ). These data indicate that MDM4 regulates the survival and proliferation of high-MDM4-expressing melanoma cells in vitro and in vivo. MDM4 protects melanoma against p53-induced apoptosis To test whether p53 inactivation underlies dependency of melanoma on high MDM4 expression, we knocked down both MDM4 and p53 in short-term cultured metastatic melanoma cell lines (MM011, MM031, MM117; Fig. 3a) . Colony formation assays indicated that the MDM4 KD-mediated growth inhibition at least partly depends on p53 (Fig. 3c) .
The two best-characterized p53-mediated antigrowth activities are induction of cell cycle arrest and apoptosis. Unexpectedly, p53 knockdown did not significantly rescue the proliferation of melanoma cells upon MDM4 knockdown (Fig. 3d) . In contrast, p53 knockdown largely rescued MDM4 knockdown cells from apoptosis (Fig. 3e) . Concomitant with apoptosis induction upon MDM4 knockdown, we observed increased recruitment of p53 to the promoters of its proapoptotic targets, BAX (encoding BCL2-associated X protein) and APAF1 (encoding apoptotic peptidase activating factor 1), and a marked increase in their transcription (Supplementary Fig. 7) . The data suggest that high MDM4 levels inhibit apoptosis in human melanoma cells by antagonizing p53.
Inhibition of the MDM4-p53 interaction restores p53 activity The reliance of melanoma cells on MDM4 for survival suggests that interfering with its interaction with p53 could restore apoptotic capability. SAH-p53-8 is a cell-penetrating, stabilized, α-helical peptide 32 that binds with high affinity to MDM4 within its p53-binding pocket and is capable of disrupting p53-MDM4 complexes 33 npg inhibition of MDM4 is a viable therapeutic strategy for melanoma, we treated a series of melanoma cell lines, including the BRAF inhibitor-sensitive melanoma M238, M249 and M229 cell lines 35 , with increasing concentrations of SAH-p53-8. SAH-p53-8 potently inhibited growth of all melanoma lines carrying wild-type p53 ( Fig. 4a and Supplementary Fig. 8 ). In contrast, melanoma cells with inactive p53 mutants did not respond to SAH-p53-8 treatment, indicating that SAH-p53-8-mediated growth inhibition depends on the presence of wild-type p53 (Fig. 4a) . Moreover, SAH-p53-8 did not markedly affect normal melanocyte growth (Fig. 4a) . SAHp53-8, but not its biologically inactive point-mutant analog SAHp53-8 F19A , induces expression of p53-target genes, including BAX, APAF1 and BBC3 (also known as PUMA; encoding BLC2 binding component 3) in both MM031 and MM011 (Fig. 4) . SAH-p53-8 induced apoptosis in all melanoma cell lines; this effect was significantly attenuated by knockdown or hypomorphic mutation of p53 ( Fig. 4 and Supplementary Fig. 9 ). Consistent with the fact that high MDM4 expression levels are associated with a reduced apoptotic response to MDM2 antagonists 36, 37 , nutlin-3 induced relatively low apoptotic activity in MM011 cells despite high expression levels of MDM2 in these cells, and it induced practically no activity in MM031 cells (Fig. 4e-g ).
We next treated melanoma cells with SAH-p53-8, nutlin-3 or a 1:1 stoichiometric combination of both compounds (Fig. 4h,i) . As expected, nutlin-3 had only a marginal cytotoxic effect on MM031 cells. In contrast, we observed marked growth inhibition in MM031 cells in response to SAH-p53-8 alone (Fig. 4h) , and we saw only a very modest increase in cytotoxicity upon combination with nutlin-3 (combination index = 0.90; combination index is calculated as described in ref. 33 ). MM011 cells, however, showed sensitivity to the single agents (Fig. 4i) and the two compounds synergize strongly, leading to enhanced cytotoxicity (combination index = 0.32). The mutant SAH-p53-8 F19A peptide did not induce any measurable cytotoxic effects in any of the cell lines (Fig. 4h,i) . Together our data indicate that all human melanoma cell lines analyzed are either highly sensitive to MDM4 inhibition either alone or in combination with MDM2 inhibition.
To test the therapeutic potential of inhibiting the p53-MDM4 interaction in vivo, we evaluated the activity of SAH-p53-8 in a MM031 mouse xenograft model. Although tumor growth rate was unaffected in vehicle-treated (vehicle was 5% (vol/vol) DMSO in D5W) mice, intravenous treatment with SAH-p53-8 significantly suppressed tumor growth (Fig. 4j) . As previously shown, histological examination of SAH-p53-8-treated mice indicated no obvious toxicity 33 . Collectively, these data show the therapeutic potential of inhibiting the MDM4-p53 interaction in melanoma.
SAH-p53-8 sensitizes melanoma to chemotherapy and BRAF (V600E) inhibition DNA-damaging agents such as Cisplatin or melphalan have yielded low response rates in the treatment of melanomas 38 . As these agents rely partly on activating the p53 pathway, we hypothesized that co-treatment with p53-MDM4 inhibitors may enhance their potency. We therefore investigated the effects of Cisplatin and melphalan alone or in combination with either nutlin-3 or SAH-p53-8 on MM011 and MM031 cell line growth. Although treatment with these agents alone yielded variable growth inhibition, cytotoxic effects were greatly potentiated by co-treatment with SAH-p53-8 ( Fig. 5a-d and Supplementary Fig. 10 ). Transcriptional induction of p53 targets was more robust in cells treated with both Cisplatin and SAH-p53-8 than in cells treated with single agents (Fig. 5e,f ) . As expected, MM031 cells expressing low levels of MDM2 responded more favorably to the combination of alkylating agents with SAH-p53-8 than to co-treatment with nutlin-3 (Fig. 5a,c) . In contrast, high expression levels of MDM2 rendered MM011 cells at least partly sensitive to nutlin-3 (Fig. 5b,d) ; identical results were obtained with melphalan Fig. 10 ). Collectively, these data suggest that targeting the MDM4-p53 interaction sensitizes melanoma cells to DNAdamaging agents.
Overcoming widespread resistance to BRAF inhibitors 39 is likely to require targeting of multiple signaling pathways. We investigated whether targeting the MDM4-p53 interaction could affect the growth of BRAF inhibitor-sensitive parental melanoma cell lines (M238 and M249) as well as BRAF-resistant sublines (M238R1 and M249R4) that were artificially derived by chronic exposure to a BRAF inhibitor 35 . All cell lines express high MDM4 protein expression levels and harbor wild-type p53. Treatment of both parental and BRAF-resistant cell lines with increasing doses of SAH-p53-8 led to decreased viability, indicating that cells that have acquired drug resistance to BRAF inhibitor remain largely sensitive to MDM4-p53 targeting (Fig. 6a) . We saw a comparable increase in expression of p53 and its target p21 in the parental and resistant lines upon SAH-p53-8 exposure (Fig. 6b) . Notably, SAH-p53-8 exposure led to a marked decrease in MDM4 protein expression levels (Fig. 6b) .
To investigate whether combined BRAF (V600E) and MDM4 inhibition synergizes to induce cytotoxicity, we treated BRAF inhibitorsensitive lines with a BRAF inhibitor, PLX4032, and with SAH-p53-8 individually or in combination (Fig. 6c) . PLX4032 alone was sufficient to decrease the viability of these cells (Fig. 6c) . Co-treatment with PLX4032 and SAH-p53-8 significantly enhanced the effect when compared with each individual compound (Fig. 6c) .
DISCUSSION
Unlike in most other tumor types, TP53 mutations are rare in melanomas, making the relevance of the p53 pathway in melanomagenesis controversial. Given our observation of MDM4 overexpression in about 65% of melanomas, we contend that MDM4 overexpression is an important oncogenic event that alters p53 function in melanoma in a large proportion of patients.
Because MDM4 overexpression is primarily detected at the protein level, its detection inevitably escaped previous investigations that focused on transcriptomic analyses. This raises a possibility that MDM4 overexpression might be an even more frequent oncogenic event than previously anticipated in other tumor types as well 23 .
At physiological levels MDM4 serves as a constitutive buffer against untoward p53 activity 23, 40, 41 ; its oncogenic activity results from its ability to attenuate p53 function 23, 24 . Consistent with this, we found that most melanoma cells depend on high MDM4 expression to survive by keeping the proapoptotic functions of p53 in check. Furthermore, we found that high MDM4 expression levels are also required, in a p53-independent manner, by melanoma cells for proliferation in culture. This raises the possibility that MDM4 possesses additional oncogenic functions, independent of p53 suppression. Although p53-independent function(s) may contribute to MDM4-mediated oncogenesis, we found that targeting the MDM4-p53 interaction was sufficient to suppress the growth of metastatic melanoma cells with wild-type p53.
Restoration of p53 function has been extensively pursued as a therapeutic approach in cancers in which, as in most melanomas, p53 function is compromised although the TP53 locus remains intact [42] [43] [44] . Several efforts have focused on blocking MDM2 as a strategy to reactivate p53 (refs. 34,45-48) , despite several caveats 49 . One major limitation of MDM2-specific therapy is that tumor cells in which MDM4 expression is high but MDM2 is low respond poorly to MDM2 inhibition 13, 33 . We found that most human melanoma cell lines express high MDM4 and low MDM2 levels and indeed respond very poorly to treatment with the MDM2-specific antagonist nutlin-3. In contrast, these cells are extremely sensitive to SAH-p53-8, thus indicating that pharmacological disruption of the MDM4-p53 interaction is required to induce p53 signaling in these cells. Note, however, that SAH-p53-8 can also suppress MDM2-p53 binding to some extent. It therefore cannot be ruled out that SAH-p53-8 effectiveness against melanoma cells with a high MDM4/MDM2 ratio depends, at least partly, on MDM2 targeting. Melanomas that express high levels of both MDM4 and MDM2 are rare, although we found that cell lines with this profile were sensitive to either SAH-p53-8 or nutlin-3 but even more sensitive to combination treatment. Therefore, whereas the majority of melanoma patients may respond poorly to single MDM2 inhibitors, they could benefit greatly from treatment with single MDM4 or dual MDM4/MDM2 antagonists.
Recent data argue that MDM4 inhibition is a more feasible and less hazardous strategy than MDM2 inhibition for restoring p53 function. For instance, genetic ablation of Mdm2 in normal adult tissues, including those that are quiescent and fully differentiated, leads to pathologies because of the induction of p53-dependent cell death 20 . Hence, toxicity after systemic exposure to potent MDM2 inhibitors is a serious concern. In contrast, ablation of Mdm4 in most adult somatic tissues leads to either modest or no phenotypic consequences 40, 41 .
Most patients with metastatic melanoma do not respond to conventional chemotherapy regimens 50 . Our results show that inhibition of npg the MDM4-p53 interaction greatly potentiates the cytotoxic effects of two widely used chemotherapeutic agents. MDM4 inhibitors could therefore be used to enhance the effectiveness of conventional therapeutic agents in the treatment of melanoma. Similarly, despite the initial success with BRAF inhibitors, chronic treatment is invariably associated with the development of drug resistance 39 . Management of BRAF inhibitor resistance is likely to be achieved through combination therapy that targets multiple pathways. We have shown that MDM4 is overexpressed in melanomas harboring mutations in BRAF and NRAS alike, that MDM4-p53 inhibition equally affects the growth of NRAS-and BRAF-mutant melanoma cells and, notably, that MDM4-p53 inhibition is equally effective at inhibiting growth of BRAF-mutant cells before or after they acquire resistance to BRAF inhibitors. We also show that combined treatment with MDM4-p53 inhibitors and BRAF inhibitors synergizes to kill melanoma cells that are sensitive to BRAF inhibition.
Our findings suggest that MDM4-p53 targeting offers a promising approach to improve the clinical benefits of BRAF inhibition. Crucially, our in vitro results predict that MDM4-p53 targeted therapy may be effective in cases when BRAF inhibitor resistance has already been acquired and in melanomas with NRAS mutations, for which no specific inhibitors exist. Prioritization should therefore be given to the preclinical development of strategies that inhibit MDM4-mediated suppression of p53 function in human melanoma.
METHODS
Methods and any associated references are available in the online version of the paper.
ONLINE METHODS
Cell culture. MM001, MM011, MM031 and MM117 cells were cultured in F10 medium with 5% FBS (FBS, HyClone) and 5% calf bovine serum (HyClone). A375 and Lu1205 cells were cultured in, respectively, RPMI and DMEM medium with 10% FBS (Sigma). M238, M248, M229 and their BRAF inhibitor resistant sublines were cultured in DMEM plus 5% FBS (HyClone).
Viral transduction.
To knock down MDM4 we used two different lentiviral shRNA expression vectors (M:5′-GTGCAGAGGAAAGTTCCAC and M(2): 5′-ACAGTCCTTCAGCTATTT). One of these vectors was described previously 51 and the other was obtained from the Mission shRNA library (Sigma). The p53 knockdown and shRNA control vectors have also been described previously 51 .
Cell growth and viability. Cell growth was measured using the WST-1 (Roche) or CellTiter-Glo (Promega) assays. Cells were seeded in triplicate in 96-well plates, and treated with chemotherapeutics: Cisplatin (Sigma) or melphalan (Sigma), SAH-p53-8 and SAH-p53-8 F19A (ref. Colony-formation assays. Cells were plated at a density between 2 × 10 3 and 32 × 10 3 cells per six-well plate and cultured for 12 days. The cells were washed with PBS 1×, fixed and stained 5 min with a 1% crystal violet in 35% methanol solution.
Flow cytometry and apoptosis assays. Cells were incubated for 2 h with BrdU (final concentration 10 µM), washed in PBS and fixed in ice-cold 70% ethanol. Cells were labeled for BrdU incorporation with an APC BrdU flow kit (BD Pharmingen no. 557892), according to the manufacturer's protocol and resuspended in 300 µl of PBS containing 20 µl of 7-AAD. For the annexin V apoptosis assay, melanoma cells were plated at a density of 1.5 × 10 6 per well in a six-well plate and were treated with SAH-p53-8 or nutlin-3 for 24 h in Opti-MEM. Cells were harvested, washed with PBS, and incubated with Alexa Fluor 488-conjugated annexin V and propidium iodide. Flow cytometry was done in the FACSCanto (BD Biosciences). Apoptosis was also measured using the Caspase-Glo 3/7 assay (Promega).
